Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 29516 results found since Jan 2013.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Detection and quantitative analysis of tumor-associated tertiary lymphoid structures
This study reviews the latest research progress on TLS detection and quantification, proposes new directions for TLS assessment, and addresses issues for the quantitative application of TLSs in the clinic.PMID:37701955 | DOI:10.1631/jzus.B2200605
Source: J Zhejiang Univ Sci ... - September 13, 2023 Category: Science Authors: Man Yang Yurou Che Kezhen Li Zengyi Fang Simin Li Mei Wang Yiyao Zhang Zhu Xu Liping Luo Chuan Wu Xin Lai Weidong Wang Source Type: research
Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma
CONCLUSIONS: These results suggest that IGFR1+&VEGF-A+ is expected to be a disadvantageous factor for prognosis in the subgroup of EGFR mutation in patients with early and locally advanced-stage lung adenocarcinoma. What's more, this study may provide the theoretical possibility to screen optimal population for a combination therapy with anti-VEGF and anti-IGFR1 in patients with early and locally advanced-stage lung adenocarcinoma.PMID:37702808 | DOI:10.1007/s00432-023-05371-0
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Wenting Liu Junling Xia Qingwu Du Jingya Wang Ting Mei Tingting Qin Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Clinical Lung Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Prolonged haematologic toxicity in CAR-T-cell therapy: A review
J Cell Mol Med. 2023 Sep 13. doi: 10.1111/jcmm.17930. Online ahead of print.ABSTRACTChimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its r...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Qi Liu Tonglin Hu Hangchao Li Yingying Shen Dijiong Wu Baodong Ye Source Type: research
Peroxisome proliferator-activated receptors as therapeutic target for cancer
J Cell Mol Med. 2023 Sep 12. doi: 10.1111/jcmm.17931. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor family. There are three subtypes of PPARs, including PPAR-α, PPAR-β/δ and PPAR-γ. They are expressed in different tissues and act by regulating the expression of target genes in the form of binding to ligands. Various subtypes of PPAR have been shown to have significant roles in a wide range of biological processes including lipid metabolism, body energy homeostasis, cell proliferation and differentiation, bone formation, tiss...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Yuqing Wang Feifei Lei Yiyun Lin Yuru Han Lei Yang Huabing Tan Source Type: research
Head and neck cancer treatment in the era of molecular medicine
Adv Cancer Res. 2023;160:205-252. doi: 10.1016/bs.acr.2023.03.004. Epub 2023 Apr 12.ABSTRACTHead and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized b...
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Subramanya Pandruvada Remi Kessler Ann Thai Source Type: research
Prognostic significance and immune characteristics of GPR27 in gastric cancer
Aging (Albany NY). 2023 Sep 12;15. doi: 10.18632/aging.205023. Online ahead of print.ABSTRACTGastric cancer (GC) is one of the most typical cancerous neoplasms occurring in the digestive system. For advanced GC, immunotherapy is the final option for them to prolong survival time. Hence, we aimed to identify new molecular targets to enhance the immunotherapy response in GC individuals. Then we applied bioinformatic analysis to explore the expression profiles of G-protein-coupled receptor 27 (GPR27) transcription and GPR27 methylation. The associations between survival of GC patients and GPR27 transcription and methylation w...
Source: Aging - September 13, 2023 Category: Biomedical Science Authors: Jun Pan Yuanjun Gao Source Type: research
Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer
CONCLUSION: The current findings suggest an oncogenic role for STEAP4 in GC, with significantly high levels being associated with poor prognosis. Investigation of the GC tumor microenvironment suggests the potential function of STEAP4 is connected with the infiltration of diverse immune cells, which may contribute to the regulation of the tumor microenvironment. In conclusion, STEAP4 may serve as a potential therapeutic target for GC to improve the immune infiltration, as well as serve as a prognostic biomarker for judging the prognosis and immune infiltration status of GC.PMID:37700807 | PMC:PMC10494559 | DOI:10.5306/wjco.v14.i8.297
Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Ze-Xuan Fang Yan-Yu Hou Zheng Wu Bing-Xuan Wu Yu Deng Hua-Tao Wu Jing Liu Source Type: research
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM
Cancer Immunol Res. 2023 Sep 12:OF1-OF2. doi: 10.1158/2326-6066.CIR-23-0667. Online ahead of print.ABSTRACTEnhancing T-cell infiltration into glioblastoma (GBM) tumors has proven challenging yet remains crucial for improving the efficacy of immunotherapy for patients with this deadly cancer. In this issue, Qin, Huang, Li, and colleagues find that inhibiting vasculature formation driven by cancer stem cells is a promising target to enhance immunotherapy in GBM. See related article by Qin et al. (2).PMID:37702792 | DOI:10.1158/2326-6066.CIR-23-0667
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Juyeun Lee Kristen E Kay Michael A Vogelbaum Justin D Lathia Source Type: research
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.PMID:37702716 | DOI:10.1158/1078-0432.CCR-23-1578
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda Young Minu K Srivastava Geoffrey Source Type: research
Macrophage memory: Types, mechanisms, and its role in health and disease
Immunology. 2023 Sep 13. doi: 10.1111/imm.13697. Online ahead of print.ABSTRACTOn the basis of the mechanisms of action and characteristics of immune effects, immunity is commonly categorized into innate and adaptive immunity. Adaptive immunity is associated with the response to non-self-entities and is characterized by high specificity and memory properties. In contrast, innate immunity has traditionally been considered devoid of memory characteristics. However, an increasing number of studies have sought to challenge this conventional immunological dogma and shown that innate immune cells exhibit a more robust and rapid ...
Source: Immunology - September 13, 2023 Category: Allergy & Immunology Authors: Xu-Hui Fang Zhi-Jing Li Chun-Yan Liu Gil Mor Ai-Hua Liao Source Type: research
Peroxisome proliferator-activated receptors as therapeutic target for cancer
J Cell Mol Med. 2023 Sep 12. doi: 10.1111/jcmm.17931. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor family. There are three subtypes of PPARs, including PPAR-α, PPAR-β/δ and PPAR-γ. They are expressed in different tissues and act by regulating the expression of target genes in the form of binding to ligands. Various subtypes of PPAR have been shown to have significant roles in a wide range of biological processes including lipid metabolism, body energy homeostasis, cell proliferation and differentiation, bone formation, tiss...
Source: J Cell Mol Med - September 13, 2023 Category: Molecular Biology Authors: Yuqing Wang Feifei Lei Yiyun Lin Yuru Han Lei Yang Huabing Tan Source Type: research
Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
Adv Cancer Res. 2023;160:253-315. doi: 10.1016/bs.acr.2023.03.005. Epub 2023 Apr 20.ABSTRACTCurrent treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and develo...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Amit Kumar Swadesh K Das Luni Emdad Paul B Fisher Source Type: research
Head and neck cancer treatment in the era of molecular medicine
Adv Cancer Res. 2023;160:205-252. doi: 10.1016/bs.acr.2023.03.004. Epub 2023 Apr 12.ABSTRACTHead and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized b...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Subramanya Pandruvada Remi Kessler Ann Thai Source Type: research
